CEVEC announces appointment of life sciences industry expert Frank Ubags as Chief Executive Officer

Cologne, Germany, April 17, 2015 - CEVEC Pharmaceuticals GmbH (CEVEC), the provider of novel human cell expression systems, today announced the appointment of Frank Ubags as Chief Executive Officer starting immediately. He replaces Wolfgang Kintzel who is moving into the investor side of the life sciences industry. He will continue to serve as an advisor to CEVEC.

Frank Ubags joined CEVEC in October 2014 as Chief Operating Officer and Managing Director. He has over 35 years of leadership experience in renowned companies. He has successfully executed major financing transactions, turn around projects, and initiated and executed major M&A transactions in both acquiring and selling companies. Frank joined the life sciences industry in 1997 as CFO of Rhein Biotech, where he led the 1999 IPO and was responsible for the transformation of Rhein Biotech into a vaccines company followed by, two years later, a trade sale to Berna Biotech. In addition, Frank’s experience has included CEO, COO and CFO positions in companies such as the German Rhein Biotech operation, Kiadis Pharma and Scil Proteins. Frank holds several advisory positions in the field of protein production.

Joachim Rautter, Chairman of the CEVEC Supervisory Board, commented: “With Frank’s financial, operational and strategic track record we are well positioned to execute our financing and growth strategies. On behalf of the Board, I would like to thank Wolfgang Kintzel for his excellent work as CEO and his strategic leadership during the last six years.”

“Our CAP® Technology is by now very well positioned in the market. It has been specifically developed to enable the industrial scale production of viral vectors for the currently exponentially growing field of gene therapy. In addition, our technology also facilitates limitless access to ‘difficult to produce’ proteins, coagulation factors and other plasma derived substances, allowing for broader, safer and less cost-intensive applications,” explained Frank Ubags, the newly appointed Chief Executive Officer of CEVEC. “Together with the whole CEVEC team, I am looking forward to fully exploit the enormous potential of our unique assets.”

About CEVEC:

CEVEC Pharmaceuticals GmbH (www.cevec.com) offers an innovative human cell expression system - CAP® Technology. The patented human cell lines are used for the production of gene therapy vectors, therapeutic proteins and novel innovative vaccines. A number of licensing transactions, both for R&D and clinical purposes, have already been concluded. CEVEC has recently formed a CMO joint venture partnership with GenIBet, Portugal for cGMP production services based on CAP® Technology.

Contact:

CEVEC Pharmaceuticals GmbH
Frank Ubags
Chief Executive Officer
T.:+49 221 46020800
E.: ubags@cevec.com

MC Services AG
Anne Hennecke
Public Relations
T.: +49 211 52925222
E.: anne.hennecke@mc-services.eu

 

CEVEC: CAP® Derived Recombinant C1 Inhibitor Matches Berinert® in Animal Study

Cologne, Germany, February 2, 2015
CEVEC Pharmaceuticals, the developer and licensor of the CAP® Technology, today announced a major milestone regarding its recombinant human CAP® cell derived C1 Esterase Inhibitor (C1Inh).

CEVEC´s CAP derived C1 Inhibitor material showed in a pivotal pharmacokinetic rat study a serum half life matching one of the two currently available, plasma derived treatments, Berinert®. All other known versions of recombinant C1 Inh, including e.g. Ruconest® from transgenic rabbits, displayed so far a significantly shorter half life than plasma derived C1 Inh. To achieve this excellent protein quality of the recombinant C1Inh, new glycosylation optimized CAP-GO cells were developed at CEVEC. This result, in combination with previously shown excellent specific activities of CAP derived C1 Inh and commercially attractive production yields using CAP-GO cells, paves now the way to develop a safer and more economic therapy for acute and prophylactic HAE indications.

Dr. Nicole Faust, CSO: “A human cell derived recombinant C1 Inhibitor is a long sought after product as an alternative to the currently available plasma derived therapies. Our promising results based on our fully scalable and cGMP compliant CAP suspension cells potentially open an entire new way to treat HAE."

Wolfgang Kintzel, CEO comments: “We are proud to offer interested parties a licensable human cell derived recombinant C1 Inhibitor with safety and production advantages after years of intense development. We’re convinced that this molecule has the potential to become the recombinant alternative of choice in the HAE therapy field. CEVEC has an increasing license customer portfolio for its CAP cell lines. Additionally, we offer a variety of biotherapeutics in pre-clinical stage. CEVEC´s customers can now also order pre-clinical, phase I and phase II material via our CMO business."

About Hereditary Angioedema (HAE)
A rare defect in the gene controlling the synthesis of the C1 Inhibitor leads to a life threatening disorder called Hereditary Angioedema (HAE), where patients suffer from episodes of edema (swelling) in various body parts including the hands, feet, face and airway. The leading current FDA approved treatments of the disease include intravenous injections of C1 Esterase Inhibitors that are purified from human serum. As with any blood or plasma derived product, these treatments are dependent on plasma supply and contain the risk of transmission of infectious agents like viruses or theoretically also the CJD agent.

About CEVEC
CEVEC is the global provider of an innovative human cell expression system - CAP Technology. The patented human cell lines are used for the production of novel innovative vaccines, gene therapy vectors and therapeutic proteins. Several recombinant biotherapeutics derived from CAP cells exhibit improved and unique clinical characteristics which in return created a convincing pipeline of clinical licensees for CEVEC. Using its proprietary technology, CEVEC has recently formed a joint venture partnership with mid-size CMOs both in Europe and newly also in the US to offer cGMP production services in CAP cells.

Contact
Wolfgang Kintzel, CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln, Germany
phone +49 (0) 221-46 02 08 – 00
Kintzel@cevec.com

CEVEC Introduces CMO Services for the cGMP Manufacturing of CAP-based Clinical Materials

Cologne, Germany, September 23, 2014
CEVEC Pharmaceuticals, the developer and licensor of the CAP Technology today announced the extension of its CAP Technology business portfolio by offering cGMP compliant Contract Manufacturing Services.
CAP-derived clinical materials comprising recombinant proteins, vaccines and gene therapy vectors are now directly available from CEVEC to support Phase I+II clinical studies.
The CAP manufacturing joint venture with Lisbon based GenIbet operates state of the art cGMP manufacturing capabilities and allows for a one-stop offer for CEVEC customers in need of preclinical and clinical development of CAP Cell-derived materials.

First CAP-based clinical material has already been produced by the GenIbet facility.

“Our vision is to become the leading independent player for human cell line based clinical materials. This is the next step in growing CEVEC along the value chain. The Contract Manufacturing business will be under the leadership of Frank Ubags, who recently joined us as COO. Frank has an impressive track record in the biopharmaceutical sector in establishing and implementing growth strategies” stated Wolfgang Kintzel, CEO at CEVEC.

About CEVEC Pharmaceuticals GmbH - www.cevec.com
CEVEC offers the human amniocyte based protein expression platform CAP for the transient and stable production of superior Biopharmaceuticals,
CAP Cells are immortalized suspension cells for stable protein production developed by CEVEC. This non-tumor origin cell line exhibits high protein expression, has been adapted to serum-free suspension culture and shows post-translational modifications that are human-like, including authentic human glycosylation patterns. The technology allows for superior yields of complex (glyco-) proteins in a shorter time frame than traditional methods and has proven to be a versatile production platform for gene therapy vectors, viruses and vaccines.


Contact:

Wolfgang Kintzel, CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln, Germany
phone +49 (0) 221-46 02 08 – 00
fax +49 (0) 221-46 02 08 – 01
info@cevec.com
www.cevec.com

CEVEC Appoints New Management Team

Cologne, Germany, September 19, 2014
CEVEC Pharmaceuticals, the developer and licensor of the CAP Technology, today announced its new management team.
Wolfgang Kintzel remains Chief Executive Officer, Dr. Nicole Faust is appointed Chief Scientific Officer, Dr. Hartmut Tintrup is appointed Chief Business Officer and Frank Ubags joins as Chief Operating Officer.

“Our vision is to become the leading independent player for human cell line based clinical materials. This management team possesses all skills, competencies and experience to achieve this ambitious target."
"I am very pleased to welcome Frank Ubags to our team. Frank has an outstanding track record in the biopharmaceutical sector in establishing and implementing growth strategies. Together with him we have now accomplished a strong management team to lead CEVEC through its next stage of corporate growth” stated Wolfgang Kintzel, CEO at CEVEC.

Wolfgang Kintzel, Chief Executive Officer, biologist by training (MSc) joined Schering/Berlex gaining quickly more responsibility in various sales and marketing functions. With now more than 18 years of experience in different roles within the pharmaceutical, medical device and biotech industry in leading European and US based organizations he had full P&L responsibility up to 100 Mio €. Wolfgang managed organizations up to 170 employees. From 2000 - 2008 he built up amaxa AG as global VP Marketing & Sales from a true start-up situation to a fully integrated company complemented with an outstanding M&A experience in 2008 when the company was sold to Lonza Group Ltd., Switzerland. Wolfgang joined CEVEC in 2009 as Managing Director. Wolfgang holds several board assignments in European biotech companies
Frank Ubags, Chief Operating Officer, has more than 35 years of business experience in renowned companies. He joined the life science business in 1997 as CFO of Rhein Biotech. He led the IPO at the Neuer Markt in 1999 and initiated and executed the transformation of Rhein Biotech into a vaccines company through a major acquisition, 2 years later followed by a sale to Berna Biotech. Frank served from 2004 as CEO of the German Rhein Biotech operation and after its sale to Dynavax, he joined Kiadis Pharma in 2006 as CFO. In 2009 he joined Scil Proteins as CFO. After a successful financing round in 2011, he took over in 2012 the COO position for the Scil Proteins CMO operation where he led the company through a successful FDA inspection and he initiated the sale of Scil Proteins Production to Wacker Biotech. Frank holds several advisory positions in the field of protein production.
Dr. Nicole Faust, Chief Scientific Officer, holds a Ph.D. in Molecular and Cell Biology. After a post-doctoral period at the EMBL, Heidelberg, she joined Artemis-Pharmaceuticals GmbH, Cologne in 1999 where she took over responsibility for the Molecular Technology group as Associate Director R&D. In 2004 she started a position with amaxa GmbH, now Lonza Cologne GmbH. As Director R&D she was responsible for developing transfection technologies, for the cell-based assay program, and for establishing and running the cell line development services. She joined CEVEC in May 2011 as VP Development & Services and was appointed Chief Scientific Officer in 2014.
Dr. Hartmut Tintrup, Chief Business Officer, served previously as VP Business Development & Licensing at CEVEC and holds a Ph.D. in Neurochemistry from Frankfurt University, Germany. He spent 16 years in various positions of increasing responsibility at leading Biotech Companies in the US and Germany. Prior to joining CEVEC he held management positions at amaxa AG and Lonza in Industrial Sales and Tactical Marketing. Hartmut joined CEVEC in 2010 was appointed Chief Business Officer in 2014.

About CEVEC Pharmaceuticals GmbH - www.cevec.com
CEVEC offers the human amniocyte-based protein expression platform CAP for the transient and stable production of superior Biopharmaceuticals, CAP Cells are immortalized suspension cells for stable protein production developed by CEVEC. This non-tumor origin cell line exhibits high protein expression, has been adapted to serum-free suspension culture and shows post-translational modifications that are human-like, including authentic human glycosylation patterns. The technology allows for superior yields of complex (glyco-) proteins in a shorter time frame than traditional methods and has proven to be a versatile production platform for gene therapy vectors, viruses and vaccines.

Contact
Wolfgang Kintzel
CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen-Straße 62
D-51105 Germany
Fon +49 (0) 221 46020800
Fax +49 (0) 221 46020801
info@cevec.com

CEVEC Signs License Agreement with Yuhan Corporation of South Korea

Cologne, Germany, December 20, 2012 / B3C newswire / - CEVEC, the developer of a novel human expression system derived from amniocytes, and Yuhan, a leading manufacturer of pharmaceutical products based in Seoul, Korea announced today the signing of a CAP-Technology license agreement. The license will enable Yuhan to utilize CEVEC’s CAP-T™ and CAP® cell expression systems for the production and development of various therapeutic proteins.

CAP-T™ CAP® cells are immortalized cell lines for transient and stable protein production developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns. The Technology allows for superior protein yields in a shorter time frame than traditional methods.

“With Yuhan Corporation we have won one of the most prestigious Asian Pharma Companies as a customer. We’re very pleased that Yuhan has chosen our CAP and CAP-T expression sytems as a pivotal platform to develop therapeutically relevant molecules. I’m convinced that the cells will have a major impact to develop more efficient biologics and will also shorten the timeline to enter clinical phases “ stated Wolfgang Kintzel, CEO at CEVEC.

Dr. Jong-Gyun Kim, Head of the Bio-Innovation Unit at Yuhan Research Institute said: “After evaluating CAP and CAP-T we are excited about the potential of CEVEC’s CAP Technology. We obtained outstanding results from transfections of various target proteins in CAP-cells and we are convinced that this expression system with it’s authentic human glycosylation profile will be of great benefit to further develop our pipeline molecules"

About CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins, vaccines and monoclonal antibodies with human glycosylation patterns. CEVEC's novel proprietary and patent-protected human CAP® and CAP-T™ expression systems are ideal for manufacturing complex biopharmaceutical molecules and various vaccines. CEVEC is licensing out its human cell-based expression platform as well as its own biobetter candidates through partnerships with renowned pharmaceutical and biotech companies.

About Yuhan
Yuhan Corporation, the leading pharmaceutical company in South Korea, is focusing its R&D capabilities on new chemical entities, new biologics, herbal medicines, and APIs for global markets. For the last 86 years, Yuhan is committed to deliver advanced and innovative medicines with a slogan “Innovative, Nimble, and Translational R&D”. In 2007, ‘Revanex’, the world’s first acid pump agonist was out-licensing to China, and is now supplied world-wide to markets in Asia. Yuhan is to become the global premiere customer-focused pharma company with value driven, globally competitive R&D capability.

Contact

Wolfgang Kintzel, CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln, Germany
fon +49 (0) 221-46 02 08 – 00
fax +49 (0) 221-46 02 08 – 01
info@cevec.com
www.cevec.com

Jong-Gyun Kim, Ph.D.
Head, BioInnovation Unit, Yuhan Corporation
416-1 Gongse-dong, Yongin-si, Korea
Tel +82 31-899-4168
Fax +82 31-275-6145
myseed@yuhan.co.kr

Cevec raised an additional amount of € 2.8 million in a Series C financing led by Peppermint VenturePartners

Cologne, Germany, 24 October 2012 – CEVEC Pharmaceuticals GmbH (CEVEC), the developer of a novel human expression system for the manufacturing of complex biopharmaceuticals and vaccines announced today that it raised an additional amount of € 2.8 million in a Series C financing led by Peppermint VenturePartners (PVP) via the new Charité Biomedical Fund. Additional financing was provided by Midas Group and existing investors Creathor Venture and NRW.Bank. The funds will be used to advance proprietary product developments in the areas of therapeutic proteins and the novel vaccine business of CEVEC.

Köln, 24.October 2012 – Die CEVEC Pharmaceuticals GmbH (CEVEC), ein Entwickler von neuen Expressionssystemen auf Basis menschlicher Zellen zur Produktion von komplexen Biopharmazeutika und Impfstoffen, hat heute den Abschluss ihrer neuen Finanzierungsrunde in Höhe von € 2,8 Mio. unter der Führung des von Peppermint VenturePartners (PVP) gemanagten Charité Biomedical Fund mitgeteilt. Weitere Investoren sind die Midas Gruppe, sowie die bestehenden Investoren Creathor Venture und NRW.Bank. Die eingeworbenen Mittel sollen zum Ausbau eigner Produktentwicklungen bei CEVEC in den Bereichen therapeutische Proteine und Impfstoffe eingesetzt werden.
 

Contact:
Wolfgang Kintzel
CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln, Germany
fon +49 (0) 221-46 02 08 - 00
fax +49 (0) 221-46 02 08 - 01
info@cevec.com

CEVEC Licenses CAP Technology to Paragon Bioservices, Inc.

Cologne, Germany, August 2, 2012 / B3C newswire / - CEVEC Pharmaceuticals, the developer of a novel, market-leading human protein expression system derived from amniocytes, and Paragon Bioservices, Inc., a leading contract research and GMP manufacturing organization with a focus on the development and manufacturing of biopharmaceuticals, announced a joint collaboration earlier today...

...whereby Paragon Bioservices would license and use CEVEC's know-how and patents (on CAP and CAP-T cell expression system) to develop stable cell lines and perform process development for the contract manufacturing of recombinant proteins and antibodies.

"We are very pleased to be working with Paragon Bioservices," said Wolfgang Kintzel, CEVEC's CEO. "Since they provide preclinical research and development services and protein production for many of the large pharmaceutical companies, we believe that our collaboration will inevitably benefit the research community at-large."

Paragon's CEO, Marco Chacón, PhD, agrees, "Even though our upstream developmental team has many years of experience in cell biology and bioprocess development, this is a highly competitive business. Everyone needs an edge to meet the outsourcing challenges of our clients. This valuable tool from CEVEC will assist us in offering clients a fully optimized human expression system that will express proteins with superior yields and in a shorter time frame than traditional methods. We look forward to a long relationship with CEVEC."

About CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins, vaccines and monoclonal antibodies with human glycosylation patterns. CEVEC's novel proprietary and patent-protected human CAP® and CAP-T T expression systems are ideal for manufacturing complex biopharmaceutical molecules and various vaccines. CEVEC is licensing out its human cell-based expression platform as well as its own biobetter candidates through partnerships with renowned pharmaceutical and biotech companies.

About Paragon Bioservices, Inc.
Paragon is a Contract Research & GMP Manufacturing Organization (CMO) delivering research, development and manufacturing services. Paragon's focus is biopharmaceuticals, including recombinant proteins, viral vectors, vaccines, VLPs, bacteriophage and stem cells. Our clients include pharmaceutical companies, biotechnology companies and federal agencies.

Contacts:


Wolfgang Kintzel
CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln, Germany
fon +49 (0) 221-46 02 08 - 00
fax +49 (0) 221-46 02 08 - 01
info@cevec.com


Marco A. Chacón, Ph.D.
President & CEO
Paragon Bioservices, Inc.
Baltimore, MD 21201
ph (410)975-4050 or (410) 975-4052
machacon@paragonbioservices.com or
sales-support@paragonbioservices.com